MoonLake Immunotherapeutics
MLTX
$54.39
-$0.49-0.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.25% | 12.41% | -28.86% | -45.84% | -77.48% |
| Total Depreciation and Amortization | 96.30% | -70.95% | 3,904.00% | -90.50% | 4.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.60% | 765.55% | -114.98% | 32.86% | 9.10% |
| Change in Net Operating Assets | -222.22% | 90.54% | -147.09% | 255.69% | -86.99% |
| Cash from Operations | -42.97% | 21.32% | -91.79% | 9.38% | -86.58% |
| Capital Expenditure | 100.00% | 80.07% | -32.83% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.81% | 138.25% | -351.92% | 166.57% | -206.88% |
| Cash from Investing | 56.91% | 138.18% | -352.79% | 166.42% | -204.62% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -33.64% | 65.06% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -- | 100.00% |
| Cash from Financing | -100.00% | 48,421.57% | -17.70% | -- | -100.00% |
| Foreign Exchange rate Adjustments | 1,680.68% | -120.76% | 230.24% | -1,814.12% | -136.96% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.47% | 146.68% | -694.03% | 128.42% | -1,690.35% |